Feasibility of adding pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O) to standard treatment for resectable high-risk gastric cancer patients

The Queen Elizabeth Hospital0 个研究点目标入组 10 人开始时间: 2020年11月17日最近更新: 2020年11月24日

适应症

试验速览

暂无简介。

•Adult patients (> 18 years of age)
•Clinical and histopathological confirmation of gastric adenocarcinoma.
•Undergoing or recommended for curative treatment for gastric adenocarcinoma
•One or more of the following oncological high-risk features must be present:
•Positive cytology in initial peritoneal lavage
•Signet cell ring pathology
•Diffuse type gastric adenocarcinoma
•Linitis plastica as per laparoscopic, endoscopic or imaging assessment
•Proximal location
•Serosal involvement of the stomach (T3/4)
•Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.

•Extra-abdominal metastatic disease and established and proven peritoneal meatstatic disease.
•Bowel obstruction requiring nasogastric tube or percutaneous endoscopic gastrostomy
•History of allergic reaction to platinum containing compounds or doxorubicin
•Severe renal impairment, myelosuppression, severe hepatic impairment, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias
•Immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system
•Pregnancy/breast feeding
•Any chronic medical or psychiatric condition that in the option of the investigators would make the subject unsuitable for the study or prevent compliance with study protocol procedures.

发起方